Department of Pharmacy Practice, Regis University School of Pharmacy, Denver, Colo.
Department of Clinical Pharmacy, University of Colorado, Denver, Colo; College of Business and Economics, American University of Armenia, Yerevan, Armenia.
J Allergy Clin Immunol Pract. 2018 Mar-Apr;6(2):536-544.e1. doi: 10.1016/j.jaip.2017.06.039. Epub 2017 Aug 26.
The degree of asthma control among school-aged children (SAC) nationally is not well understood.
The objective of this study was to characterize poor control among SAC (aged 6-17 years) in the United States.
This was a retrospective analysis of the 2007-2013 Medical Expenditure Panel Survey. Indicators of poor control included exacerbation in previous year; use of >3 canisters of short-acting β-agonist (SABA) in 3 months; and asthma-specific (AS) emergency department (ED) or inpatient (IP) visits. Treatment indicators included daily controller medication and peak flow meter use. Negative binomial regression was used for health resource utilization (HRU); generalized linear models with log-link were used for health care expenditures.
There were 44,320 SAC, of whom 5,890 had asthma. The prevalence of poor control and treatment among SAC with asthma were as follows: exacerbation (59%), >3 canisters of SABA (4%), ED/IP visit (3%), daily controller (19%), peak flow (12%). In 2013, 3.4 million SAC had an asthma exacerbation and 200,000 had an AS ED/IP visit. SAC with asthma and an exacerbation had 18.9 times more annual AS ED visits (and 43.3 times more AS hospitalizations) than SAC with asthma but no exacerbation. SAC with asthma and an indicator of poor control incurred greater annual all-cause expenditures than SAC without asthma ($US 2015): $1,144 (exacerbation), $1,859 (≥3 canisters of SABA), and $3,063 (ED/IP visit). Use of daily controller medication was low even among SAC with poor control (27% to 61%).
Renewed and vigilant asthma management and treatment is necessary to mitigate the current and long-term public health effects and expenditures associated with poor asthma control.
目前,美国学龄儿童(SAC)的哮喘控制程度尚不清楚。
本研究旨在描述美国 SAC(6-17 岁)的哮喘控制不佳情况。
这是对 2007-2013 年医疗支出调查的回顾性分析。哮喘控制不佳的指标包括前一年的加重情况;过去 3 个月内使用超过 3 罐短效 β-激动剂(SABA);以及哮喘特定(AS)急诊室(ED)或住院(IP)就诊。治疗指标包括每日控制器药物和峰值流量计的使用。采用负二项回归模型分析卫生资源利用(HRU);采用对数链接的广义线性模型分析医疗保健支出。
共纳入 44320 名 SAC,其中 5890 名为哮喘患者。SAC 哮喘患者的哮喘控制不佳和治疗情况如下:加重(59%)、使用超过 3 罐 SABA(4%)、ED/IP 就诊(3%)、每日控制器药物(19%)、峰值流量计(12%)。2013 年,有 340 万 SAC 发生哮喘加重,有 20 万 SAC 发生 AS ED/IP 就诊。与无哮喘加重的哮喘患者相比,哮喘加重的 SAC 年 AS ED 就诊次数多 18.9 倍(AS 住院治疗多 43.3 倍)。有哮喘且控制不佳指标的 SAC 比无哮喘的 SAC 年总支出更高(2015 年美元):哮喘加重的 SAC 支出为 1144 美元,使用超过 3 罐 SABA 的 SAC 支出为 1859 美元,ED/IP 就诊的 SAC 支出为 3063 美元。即使在控制不佳的 SAC 中,每日控制器药物的使用率也较低(27%至 61%)。
为减轻当前和长期与哮喘控制不佳相关的公共卫生影响和支出,需要加强和警惕哮喘管理和治疗。